Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|December 5, 2022
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolConnie B Newman, Jonathan A TobertJournal of Clinical Lipidology|September 1, 2016
The nocebo effect in the context of statin intoleranceJonathan A Tobert, Connie B NewmanEuropean Journal of Preventive Cardiology|August 31, 2015
Statin tolerability: In defence of placebo-controlled trialsJonathan A Tobert, Connie B NewmanNature Reviews. Drug Discovery|June 20, 2003
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitorsJonathan A TobertEndocrinology and Metabolism Clinics of North America|August 13, 2022
LDL Cholesterol-How Low Can We Go?Jonathan A TobertEndocrinology and Metabolism Clinics of North America|August 13, 2022
Safety of Statins and Nonstatins for Treatment of DyslipidemiaConnie B NewmanJournal of Women'S Health (2002)|December 10, 2020
Mortality in COVID-19: Further Evidence for a Sex-Based Difference in the OpenSAFELY StudyConnie B NewmanBest Practice & Research. Clinical Endocrinology & Metabolism|June 2, 2022
Effects of endocrine disorders on lipids and lipoproteinsConnie B NewmanExpert Opinion on Pharmacotherapy|December 2, 2004
Simvastatin: a reviewTerje R Pedersen, Jonathan A TobertJournal of the American College of Cardiology|April 25, 2020
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus SeminarDavid Preiss, Jonathan A Tobert, G Kees Hovingh, et al.Pageof 4